Statin Use Is Prospectively Associated With New-Onset Diabetes After Transplantation in Renal Transplant Recipients

Tamas Szili-Torok, Stephan J. L. Bakker, Uwe J. F. Tietge*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE New-onset diabetes after transplantation (NODAT) is frequent and worsens graft and patient outcomes in renal transplant recipients (RTRs). In the general population, statins are diabetogenic. This study investigated whether statins also increase NODAT risk in RTRs. RESEARCH DESIGN AND METHODS From a prospective longitudinal study of 606 RTRs (functioning allograft >1year,single academic center, follow-up: median 9.6 [range, 6.6–10.2] years), 95 patients using statins were age-and sex-matched to RTRs not on statins (all diabetes-free at inclusion). RESULTS NODAT incidence was 7.2% (73.3% of these on statins). In Kaplan-Meier (log-rank test, P 5 0.017) and Cox regression analyses (HR 3.86 [95% CI 1.21–12.27]; P 5 0.022), statins were prospectively associated with incident NODAT, even independent of several relevant confounders including immunosuppressive medication and biomarkers of glucose homeostasis. CONCLUSIONS This study demonstrates that statin use is prospectively associated with the development of NODAT in RTRs independent of other recognized risk factors.

Original languageEnglish
Pages (from-to)1945-1947
Number of pages3
JournalDiabetes Care
Volume43
Issue number8
DOIs
Publication statusPublished - Aug-2020

Keywords

  • FLUVASTATIN
  • RISK

Cite this